Zelluna Immunotherapy, a Norway-based biotech company, has named Arjan Roozen as its new chief technology officer, it was reported on Friday.

Roozen, who earlier headed up the GMP solutions and manufacturing team at French cell therapy group, Cellectis, comes with expertise in microbiology and molecular microbiology. Roozen's career history has also seen him serve in various positions for Pharmacell, which was recently acquired by Lonza.

Miguel Forte, Zelluna's chief executive officer, said, 'Zelluna appointed Arjan specifically for his wide-ranging knowledge in key areas of cell therapy product manufacturing. His experience, acquired on both sides of the Atlantic will provide invaluable for Zelluna in its immediate focus of delivering clinical proof of concept of its TCRs in adoptive cell therapy for solid cancers. He will play a big part in the execution of Zelluna's manufacturing strategy for clinical trials and commercialisation.'